US Stock MarketDetailed Quotes

FOLD Amicus Therapeutics

Watchlist
  • 11.420
  • -0.160-1.38%
Close Oct 31 16:00 ET
  • 11.420
  • 0.0000.00%
Post 16:04 ET
3.39BMarket Cap-29282P/E (TTM)

Amicus Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Amicus Therapeutics Q3 2024 Estimates Date

Currency：USDNov 6, 2024

Estimate YoY
Revenue
134.96M
+30.40%
EPS
<0.01
+101.72%
Analyst Rating
Strong Buy

Oct 31, 2024

Amicus Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 12 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 145.530M--
Nov 6, 20242024/Q3-- / 134.962M--
Aug 8, 20242024/Q2126.669M / 121.244M--
May 9, 20242024/Q1110.403M / 111.186M--
Feb 28, 20242023/Q4115.082M / 115.047M--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 145.530M--
Nov 6, 20242024/Q3-- / 134.962M--
Aug 8, 20242024/Q2126.669M / 121.244M--
May 9, 20242024/Q1110.403M / 111.186M--
Feb 28, 20242023/Q4115.082M / 115.047M--

Unlock Free Earnings Estimates

Amicus Therapeutics Earnings Reports

  • Amicus Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 8 16:48 ET

  • Amicus Therapeutics | 10-Q: Q1 2024 Earnings Report

    May 9 16:08 ET

  • Amicus Therapeutics | 10-K: FY2023 Annual Report

    Feb 28 22:44 ET

  • Amicus Therapeutics | 10-Q: Q3 2023 Earnings Report

    Nov 8, 2023 16:02 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Oct 31, 2024

    Strong Buy

    • Buy

      87.50%

    • Hold

      12.50%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data